Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.59 |
| ▸ | CIT | O14578 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 4/20 | 0.46 |
| ▸ | BTK | Q06187 | 4/20 | 0.46 |
| ▸ | MELK | Q14680 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009446 | 0.93 | JAK1 (0.61) | JAK1CITJAK2KMT2AROCK2 | |
| SCHEMBL30008969 | 0.91 | JAK1 (0.58) | JAK1CITJAK2KMT2AROCK2 | |
| SCHEMBL30009617 | 0.80 | JAK1 (0.63) | JAK1CITJAK2ROCK2CYP3A4 | |
| SCHEMBL30009442 | 0.79 | CIT (0.62) | JAK1CITJAK2ROCK2CYP3A4 | |
| SCHEMBL30009593 | 0.75 | RAB9A (0.51) | CITJAK2CYP1A2CYP2C19KMT2A | |
| SCHEMBL30009316 | 0.75 | JAK1 (0.54) | JAK1CITIKBKBCHUK | |
| SCHEMBL28871098 | 0.75 | CIT (0.63) | JAK1CITJAK2ROCK2CYP3A4 | |
| SCHEMBL20917863 | 0.75 | JAK1 (1.00) | JAK1 | |
| SCHEMBL30009538 | 0.72 | KIT (0.69) | JAK1CITJAK2ROCK2LIMK1 | |
| SCHEMBL30009347 | 0.72 | JAK2 (0.55) | JAK1CITJAK2ROCK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885CIT 417/4885JAK2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.